VERONA PHARMA P/S (NASDAQ:VRNA) and Provectus Biopharmaceuticals (OTCMKTS:PVCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.
Valuation and Earnings
This table compares VERONA PHARMA P/S and Provectus Biopharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|VERONA PHARMA P/S||N/A||N/A||-$26.56 million||($2.02)||-2.23|
|Provectus Biopharmaceuticals||N/A||N/A||-$8.15 million||N/A||N/A|
Risk & Volatility
VERONA PHARMA P/S has a beta of -0.98, indicating that its stock price is 198% less volatile than the S&P 500. Comparatively, Provectus Biopharmaceuticals has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for VERONA PHARMA P/S and Provectus Biopharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|VERONA PHARMA P/S||0||0||2||0||3.00|
VERONA PHARMA P/S currently has a consensus target price of $37.50, indicating a potential upside of 733.33%. Given VERONA PHARMA P/S’s higher probable upside, research analysts plainly believe VERONA PHARMA P/S is more favorable than Provectus Biopharmaceuticals.
Insider & Institutional Ownership
56.0% of VERONA PHARMA P/S shares are owned by institutional investors. Comparatively, 0.0% of Provectus Biopharmaceuticals shares are owned by institutional investors. 4.5% of Provectus Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares VERONA PHARMA P/S and Provectus Biopharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|VERONA PHARMA P/S||N/A||-46.73%||-39.90%|
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Provectus Biopharmaceuticals Company Profile
Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing drugs based on halogenated xanthenes for oncology and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.